HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Halozyme Therapeutics, maintaining a price target of $65. This suggests confidence in the company's future performance.
October 25, 2024 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Halozyme Therapeutics, maintaining a price target of $65. This suggests confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $65 price target by HC Wainwright & Co. indicates a positive outlook for Halozyme Therapeutics. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100